January 29, 2018 / 10:50 PM / 3 months ago

BRIEF-Vistagen Therapeutics ‍Prepares To Initiate Its Phase 2 Study Of Av-101 For Major Depressive Disorder

Reuters Staff

1 Min Read

Jan 29 (Reuters) - Vistagen Therapeutics Inc:

* VISTAGEN THERAPEUTICS INC - ‍PREPARES TO INITIATE ITS PHASE 2 STUDY OF AV-101 FOR MAJOR DEPRESSIVE DISORDER Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

BRIEF-Vistagen Therapeutics ‍Prepares To Initiate Its Phase 2 Study Of Av-101 For Major Depressive Disorder​

BRIEF-Vistagen Therapeutics ‍Prepares To Initiate Its Phase 2 Study Of Av-101 For Major Depressive Disorder